# NCT06040541 (NCT06040541)

> Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06040541
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Revolution Medicines, Inc.
- Conditions: Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Advanced Solid Tumors
- Interventions: RMC-9805; RMC-6236
- Enrollment: 604
- Primary outcome: Adverse events
- Primary outcome: Dose Limiting Toxicities

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06040541